

# Critical Limb Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/CA70654B7C5CEN.html>

Date: May 2024

Pages: 136

Price: US\$ 6,499.00 (Single User License)

ID: CA70654B7C5CEN

## Abstracts

The 7 major critical limb ischemia markets reached a value of US\$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.21% during 2024-2034.

The critical limb ischemia market has been comprehensively analyzed in IMARC's new report titled "Critical Limb Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Critical limb ischemia (CLI) is a severe form of peripheral arterial disease (PAD) that occurs when there is a significant narrowing or blockage of the arteries that carry blood to the legs and feet. It is a progressive condition that can cause tissue damage, chronic pain, and non-healing wounds, as well as lead to amputation of the affected limb. The most typical symptoms of this disorder include intense foot or leg pain, smooth, hairless, shiny, or very dry feet, skin discoloration, discharge from gangrene, thick toenails, slow-healing sores, weak pulse in the legs or feet, etc. Individuals suffering from CLI may also experience cold hands, feet, or legs, skin infections, loss of muscle mass, fainting, and femoral bruit. The diagnosis of this ailment is based on a review of the patient's symptoms and other medical problems. Some of the common investigations to confirm a diagnosis and stage disease severity include computerized tomography scans, magnetic resonance imaging studies, an ankle-brachial index test, angiograms, doppler ultrasounds, etc. The healthcare provider may also perform Buerger's test to assess arterial sufficiency among patients.

The rising cases of hyperlipidemia due to high cholesterol levels, which cause narrowed or blocked arteries, are primarily driving the critical limb ischemia market. In addition to this, the elevating incidences of several associated risk factors, including smoking,

sedentary lifestyles, high blood pressure, obesity, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as beta-blockers, antiplatelet drugs, statins, etc., to prevent clots, control cholesterol levels, decrease blood pressure, and improve blood flow is also creating a positive outlook for the market. Apart from this, the widespread adoption of the pedal-plantar loop technique for percutaneous revascularization of the foot arteries, since it can facilitate better inflow and outflow from both posterior and anterior tibial vessels, is further bolstering the market growth. Additionally, the escalating utilization of intermittent pneumatic compression devices to reduce resting pain, as well as improve healing rates and physical functions in patients unsuitable for amputation, is acting as another significant growth-inducing factor. Besides this, the rising usage of stem cell-based therapy, which prolongs limb survival, decreases the speed of symptom progression, and enhances the quality of life, is expected to drive the critical limb ischemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the critical limb ischemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for critical limb ischemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the critical limb ischemia market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the critical limb ischemia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the critical limb ischemia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current critical limb ischemia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the critical limb ischemia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the critical limb ischemia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the critical limb ischemia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of critical limb ischemia across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of critical limb ischemia by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of critical limb ischemia by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with critical limb ischemia across the seven major markets?

What is the size of the critical limb ischemia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of critical limb ischemia?

What will be the growth rate of patients across the seven major markets?

### Critical Limb Ischemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for critical limb ischemia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the critical limb ischemia market?

What are the key regulatory events related to the critical limb ischemia market?

What is the structure of clinical trial landscape by status related to the critical limb ischemia market?

What is the structure of clinical trial landscape by phase related to the critical limb ischemia market?

What is the structure of clinical trial landscape by route of administration related to the critical limb ischemia market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 CRITICAL LIMB ISCHEMIA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 CRITICAL LIMB ISCHEMIA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 CRITICAL LIMB ISCHEMIA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 CRITICAL LIMB ISCHEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 CRITICAL LIMB ISCHEMIA - UNMET NEEDS**

## **10 CRITICAL LIMB ISCHEMIA - KEY ENDPOINTS OF TREATMENT**

## **11 CRITICAL LIMB ISCHEMIA - MARKETED PRODUCTS**

- 11.1 List of Critical Limb Ischemia Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.



## **12 CRITICAL LIMB ISCHEMIA - PIPELINE DRUGS**

### 12.1 List of Critical Limb Ischemia Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 YQ23 - New Beta Innovation

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

#### 12.1.2 ASCT 01 - Lifecells LLC

##### 12.1.2.1 Drug Overview

##### 12.1.2.2 Mechanism of Action

##### 12.1.2.3 Clinical Trial Results

##### 12.1.2.4 Safety and Efficacy

##### 12.1.2.5 Regulatory Status

#### 12.1.3 CLBS12 - Lisata Therapeutics

##### 12.1.3.1 Drug Overview

##### 12.1.3.2 Mechanism of Action

##### 12.1.3.3 Clinical Trial Results

##### 12.1.3.4 Safety and Efficacy

##### 12.1.3.5 Regulatory Status

#### 12.1.4 ACP 01 - Hemostemix

##### 12.1.4.1 Drug Overview

##### 12.1.4.2 Mechanism of Action

##### 12.1.4.3 Clinical Trial Results

##### 12.1.4.4 Safety and Efficacy

##### 12.1.4.5 Regulatory Status

#### 12.1.5 REX-001 - Rexgenero

##### 12.1.5.1 Drug Overview

##### 12.1.5.2 Mechanism of Action

##### 12.1.5.3 Clinical Trial Results

##### 12.1.5.4 Safety and Efficacy

##### 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. CRITICAL LIMB ISCHEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. CRITICAL LIMB ISCHEMIA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 CRITICAL LIMB ISCHEMIA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Critical Limb Ischemia - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Critical Limb Ischemia - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Critical Limb Ischemia - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Critical Limb Ischemia - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Critical Limb Ischemia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Critical Limb Ischemia - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)

- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Critical Limb Ischemia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Critical Limb Ischemia - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Critical Limb Ischemia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Critical Limb Ischemia - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Critical Limb Ischemia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Critical Limb Ischemia - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Critical Limb Ischemia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Critical Limb Ischemia - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Critical Limb Ischemia - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Critical Limb Ischemia - Access and Reimbursement Overview

## **16 CRITICAL LIMB ISCHEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 CRITICAL LIMB ISCHEMIA MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 CRITICAL LIMB ISCHEMIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Critical Limb Ischemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/CA70654B7C5CEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CA70654B7C5CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

